Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: results from an international phase III trial.

Authors
Vinik, A
Bottomley, A
Korytowsky, B
Bang, Y
Raoul, J
Valle, Juan W
Metrakos, P
Hörsch, D
Mundayat, R
Reisman, A
Wang, Z
Chao, R
Raymond, E
Affiliation
Strelitz Diabetes Research Center and Neuroendocrine Unit, Eastern Virginia Medical School, Strelitz Diabetes Center, Norfolk, VA, USA.
Issue Date
2016-12

Metadata
Show full item record
Abstract
The objective of this analysis was to compare patient-reported outcomes and health-related quality of life (HRQoL) in a pivotal phase III trial of sunitinib versus placebo in patients with progressive, well-differentiated pancreatic neuroendocrine tumors (NCT00428597).
Citation
Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: results from an international phase III trial. 2016, 11 (6):815-824 Target Oncol
Journal
Targeted Oncology
URI
http://hdl.handle.net/10541/620081
DOI
10.1007/s11523-016-0462-5
PubMed ID
27924459
Type
Article
Language
en
ISSN
1776-260X
Collections